NASDAQ:INVA - Innoviva Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.67 +0.20 (+1.03 %) (As of 01/22/2019 06:00 AM ET)Previous Close$19.47Today's Range$19.48 - $19.8152-Week Range$13.26 - $19.82Volume663,244 shsAverage Volume845,558 shsMarket Capitalization$1.99 billionP/E Ratio11.24Dividend YieldN/ABeta2 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California. Receive INVA News and Ratings via Email Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 Webwww.inva.com Phone650-238-9600Debt Debt-to-Equity RatioN/A Current Ratio28.23 Quick Ratio28.23Price-To-Earnings Trailing P/E Ratio11.24 Forward P/E Ratio10.30 P/E GrowthN/A Sales & Book Value Annual Sales$217.22 million Price / Sales9.15 Cash Flow$1.4992 per share Price / Cash Flow13.12 Book Value($2.38) per share Price / Book-8.26Profitability EPS (Most Recent Fiscal Year)$1.17 Net Income$134.14 million Net Margins75.67% Return on Equity-110.01% Return on Assets62.76%Miscellaneous Employees12 Outstanding Shares101,040,000Market Cap$1.99 billion OptionableOptionable Innoviva (NASDAQ:INVA) Frequently Asked Questions What is Innoviva's stock symbol? Innoviva trades on the NASDAQ under the ticker symbol "INVA." How were Innoviva's earnings last quarter? Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings data on Wednesday, October, 31st. The biotechnology company reported $0.43 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.49 by $0.06. The biotechnology company had revenue of $61.70 million for the quarter, compared to analysts' expectations of $64 million. Innoviva had a negative return on equity of 110.01% and a net margin of 75.67%. The company's revenue for the quarter was up 27.0% on a year-over-year basis. During the same period last year, the business earned $0.21 earnings per share. View Innoviva's Earnings History. When is Innoviva's next earnings date? Innoviva is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Innoviva. What price target have analysts set for INVA? 2 analysts have issued 1-year target prices for Innoviva's shares. Their predictions range from $16.00 to $16.00. On average, they anticipate Innoviva's share price to reach $16.00 in the next year. This suggests that the stock has a possible downside of 18.7%. View Analyst Price Targets for Innoviva. What is the consensus analysts' recommendation for Innoviva? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innoviva. Has Innoviva been receiving favorable news coverage? Press coverage about INVA stock has trended very positive on Tuesday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innoviva earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are some of Innoviva's key competitors? Some companies that are related to Innoviva include Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), Catalent (CTLT), United Therapeutics (UTHR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY) and Amneal Pharmaceuticals (AMRX). Who are Innoviva's key executives? Innoviva's management team includes the folowing people: Mr. Geoffrey Hulme, Interim Principal Exec. OfficerMs. Marianne Zhen, Chief Accounting Officer (Age 50)Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VPDr. Kevin Kwok, Head of Talent Acquisition & StrategyDr. Edmund J. Moran Ph.D., VP and R&D Program Leader (Age 58) Who are Innoviva's major shareholders? Innoviva's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include TrimTabs Asset Management LLC (0.06%), Alpha Windward LLC (0.03%), Diligent Investors LLC (0.03%), Louisiana State Employees Retirement System (0.03%) and Bowling Portfolio Management LLC (0.01%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva. Which major investors are selling Innoviva stock? INVA stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and Diligent Investors LLC. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva. Which major investors are buying Innoviva stock? INVA stock was acquired by a variety of institutional investors in the last quarter, including TrimTabs Asset Management LLC, Alpha Windward LLC and Bowling Portfolio Management LLC. View Insider Buying and Selling for Innoviva. How do I buy shares of Innoviva? Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Innoviva's stock price today? One share of INVA stock can currently be purchased for approximately $19.67. How big of a company is Innoviva? Innoviva has a market capitalization of $1.99 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe. What is Innoviva's official website? The official website for Innoviva is http://www.inva.com. How can I contact Innoviva? Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected] MarketBeat Community Rating for Innoviva (NASDAQ INVA)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 231 (Vote Outperform)Underperform Votes: 283 (Vote Underperform)Total Votes: 514MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2019 by MarketBeat.com StaffFeatured Article: Is it better to buy a fund with a higher or lower NAV?